

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (original) An IL-9 antibody comprising a variable heavy (VH) domain having an amino acid sequence of the VH domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
2. (original) An IL-9 antibody comprising a variable light (VL) domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
3. (original) The IL-9 antibody of claim 1 further comprising a VL domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
4. (original) An IL-9 antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
5. (original) The IL-9 antibody of claim 4, wherein the antibody comprises a VH CDR having an amino acid sequence of a VH CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
6. (original) The IL-9 antibody of claim 4, wherein the antibody comprises a VL CDR having an amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
7. (original) The IL-9 antibody of claim 5 further comprising a VL CDR having the amino acid sequence of a VL CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

8. (original) The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
9. (original) The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
10. (original) The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
11. (original) The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
12. (original) The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
13. (original) The IL-9 antibody of claim 9, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
14. (original) The IL-9 antibody of claim 11, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
15. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

16. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
17. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
18. (original) The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
19. (original) The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
20. (original) The IL-9 antibody of claim 16, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
21. (original) The IL-9 antibody of claim 18, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
22. (original) The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
23. (original) The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

24. (original) The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
25. (original) The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
26. (original) The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
27. (original) The IL-9 antibody of claim 23, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
28. (original) The IL-9 antibody of claim 25, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
29. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
30. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
31. (original) The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

32. (original) The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
33. (original) The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
34. (original) The IL-9 antibody of claim 30, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
35. (original) The IL-9 antibody of claim 32, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
36. (original) The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
37. (original) The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
38. (original) The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

39. (original) The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
40. (original) The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
41. (original) The IL-9 antibody of claim 37, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
42. (original) The IL-9 antibody of claim 39, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
43. (original) The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
44. (original) The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
45. (original) The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

46. (original) The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
47. (original) The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
48. (original) The IL-9 antibody of claim 44, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
49. (original) The IL-9 antibody of claim 46, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
50. (original) The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
51. (original) The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
52. (original) The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

53. (original) The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
54. (original) The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
55. (original) The IL-9 antibody of claim 51, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
56. (original) The IL-9 antibody of claim 53, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
57. (original) The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
58. (original) The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
59. (original) The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.



60. (original) The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
61. (original) The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
62. (original) The IL-9 antibody of claim 58, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
63. (original) The IL-9 antibody of claim 60, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
64. (original) The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
65. (original) The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
66. (original) The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

67. (original) The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
68. (original) The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
69. (original) The IL-9 antibody of claim 65, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
70. (original) The IL-9 antibody of claim 67, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
71. (original) The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
72. (original) The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
73. (original) The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

74. (original) The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
75. (original) The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
76. (original) The IL-9 antibody of claim 72, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
77. (original) The IL-9 antibody of claim 74, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
78. (original) The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
79. (original) The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
80. (original) The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

81. (original) The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
82. (original) The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
83. (original) The IL-9 antibody of claim 79, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
84. (original) The IL-9 antibody of claim 81, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
85. (original) The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is a human or humanized antibody.
86. (original) The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is conjugated to a detectable substance or a therapeutic agent.
87. (original) A pharmaceutical composition comprising the IL-9 antibody of claim 1, 2 or 3, and a pharmaceutically acceptable carrier.

Claims 88-100 (canceled).

101. (original) A pharmaceutical composition comprising the IL-9 antibody of claim 1, 2 or 3, and a pharmaceutically acceptable carrier.
102. (original) An article of manufacture comprising a packaging material and a pharmaceutical agent contained within said packaging material, wherein said

pharmaceutical agent comprises the IL-9 antibody of claim 1, 2 or 3 and a pharmaceutically acceptable carrier.

103. (original) An IL-9 antibody, wherein said IL-9 antibody has an association rate constant or  $k_{on}$  rate of at least  $10^5 \text{ M}^{-1} \text{ s}^{-1}$ .
104. (original) The IL-9 antibody of claim 103, wherein said association rate constant or  $k_{on}$  rate is at most  $10^{11} \text{ M}^{-1} \text{ s}^{-1}$ .
105. (original) An IL-9 antibody, wherein said IL-9 antibody has a dissociation rate constant or  $k_{off}$  rate of less than about  $2 \times 10^{-4} \text{ s}^{-1}$ .
106. (original) The IL-9 antibody of claim 105, wherein said dissociation rate constant or  $k_{off}$  is greater than  $10^{-11} \text{ s}^{-1}$ .
107. (original) An IL-9 antibody, wherein said IL-9 antibody has an affinity constant ( $K_a$ ) of at least  $10^7 \text{ M}^{-1}$ .
108. (original) The antibody of claim 107, wherein said affinity constant is at most  $5 \times 10^{11} \text{ M}^{-1}$ .
109. (original) An IL-9 antibody, wherein said IL-9 antibody has dissociation constant ( $K_d$ ) of less than  $10^{-9} \text{ M}$ .
110. (original) The antibody of claim 109, wherein said dissociation constant is greater than  $6 \times 10^{-12} \text{ M}$ .